Taking into consideration the multiparametric nature of systemic lupus erythematosus (SLE), the severity and variability of symptoms and the lack of effective therapeutic approaches, this study took advantage of the recently described role of soluble major histocompatibility complex class II (sMHCII) molecules in maintaining tolerance to the organism and attempted to apply sMHCII proteins as a treatment to murine SLE experimental models in vitro as well as in vivo. After breaking tolerance to DNA in vitro, which was accompanied by development of specific anti-dsDNA antibodies, syngeneic or allogeneic sMHCII molecules, purified from healthy mouse serum, could significantly reduce the specific antibody levels and drive the system towards immunosuppression, as assessed by specific marker analysis on T cells and cytokine production by flow cytometry and ELISA, respectively. The in vivo experimental model consisted of pristaneinduced SLE symptoms to BALB/c mice, which developed maximal levels of anti-dsDNA 2 months after pristane inoculation. Syngeneic or allogeneic sMHCII administration could alleviate pristane-induced symptoms, significantly decrease specific anti-dsDNA antibody production and develop immunosuppression to the host, as manifested by increase of CD4 + CTLA-4 + and CD4 + CD25 + cell populations in the spleen. Thus, the results presented in this study introduced the ability of sMHCII proteins to suppress specific autoantigen response, opening new areas of research and offering novel therapeutic approaches to SLE with expanding features to other autoimmune diseases.
| INTRODUCTION
Systemic lupus erythematosus (SLE) is the most complex systemic autoimmune disease affecting a wide range of tissues and organs. 1 It is characterized by autoantibody formation, immune complex deposition and end-organ damage. The generated antibodies are directed against single-and double-stranded deoxyribonucleic acid (DNA), ribonucleic acid, histones, other nuclear antigens including Smith, Ro, La as well as cytoplasmic antigens, cardiolipin and phospholipids. Autoantibodies are known to be produced during the early stages of the disease and offer the usual clinical trustworthy examination for diagnosis. The detection of antinuclear antibodies (ANAs) highly correlates with SLE diagnosis in >95% of patients. 2 Mechanisms like epitope spreading through molecular mimicry, impaired apoptotic cell clearance, genetic disorders and environmental influence have been correlated with lupus development. However, regardless of the initial cause, the common feature of these mechanisms is breaking self-tolerance. Lupus therapy has been subject of intense experimentation, yet no effective treatment is available. 3 The commonly used therapies include (1) non-steroidal antiinflammatory drugs which are used to treat pain, swelling
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because of MHC polymorphism, generalized therapies for autoimmunities aimed to re-establish tolerance to a self antigen cannot be effectively applied to all patients. Latest findings indicate that soluble class II major histocompatibility complex (sMHCII) antigens loaded with selfpeptides play an important role in tolerance maintenance. [5] [6] [7] Antigen-specific tolerοgenic stimulation has been shown to increase serum sMHCII levels as compared to the corresponding immunogenic stimulus in mice in vitro as well as in vivo, 8 while other studies indicate that CD4-positive T cells isolated from tolerant mice secrete serum MHCdependent tolerosomes. 9 Indeed, sMHCII antigens are being detected in almost all body fluids, and although their role and origin are still unclear, many pathological conditions including viral encephalitis, rheumatoid arthritis, pathologic pregnancies, asthma, AIDS, chronic hepatitis C, acute chronic uveitis and melanoma [10] [11] [12] [13] [14] [15] [16] [17] [18] have been showing divergence of sMHCII levels from control values. Soluble MHCII proteins show a molecular weight of 60 kd, which is higher than the molecular weight of membrane MHCII molecules. 7, 19 In the last decade, important knowledge has been acquired as to their regulatory role on the immune response. Serum-isolated syngeneic sMHCII proteins were shown to stimulate spleen cell proliferation, their major target being the CD4-positive cell population. Inhibition of the CD4 co-receptor using specific neutralizing antibodies destroyed the sMHCII-mediated proliferative activity, while sMHCII successfully antagonized surface MHCII antigens for binding. 20 At the physiological level, sMHCII proteins were shown to suppress not only an antigen-specific but also antigen-non-specific immune activation, correlated with increase of CD25 and CTLA-4 and decrease of CD28 expression on naive CD4-positive cells. Additionally, it was shown that sMHCII decreased IL-2 production, while increasing IL-10 production, which could account for another mechanism of non-specific suppression. In addition, these molecules inhibited phosphorylation of ZAP-70 and especially LAT proteins in the downstream pathways of TCR activation signalling. 7 Thus, sMHCII antigens could be considered as potent regulators of the immune response.
Taking advantage of the above properties of sMHCII, this study examined whether syngeneic or allogeneic sMHCII proteins could alleviate SLE symptoms in an experimental mouse model in vitro as well as in vivo. Indeed, mass spectroscopy analysis has demonstrated a significant amount of self-peptides loaded onto serum sMHCII, including self-peptides related to nuclear proteins such as DNA-binding protein SATB1, DNA-directed RNA polymerase III subunit RPC2, DNA repair protein REV1, nuclear mitotic apparatus protein 1, nucleolar protein 8, DNA topoisomerase 1, nuclear RNA export factor 1, DNA-binding protein RFX8 as well as DNA polymerase epsilon catalytic subunit A loaded onto sMHCII, 7 which are relevant to SLE. The in vitro experimental model applied in this study consisted of dsDNA tolerance breakdown, while the in vivo experimental model consisted of pristane administration to BALB/c mice. 21, 22 
| Antibodies
Mouse anti-IA/IE mAb (HB-225 TM hybridoma: Mus musculus (myeloma), hamster, Armenian B cell, reacts with a monomorphic determinant on the I-A and I-E region, IgG isotype, generous gift from Dr R Steinman, Rockefeller University, NY) was purified from culture supernatants, used at the concentration 0.1 lg/mL in ELISA experiments and was covalently linked to magnetic beads coupled with sheep anti-mouse IgG for protein purification procedures (see below). Mouse anti-IA k mAb (Becton Dickinson, New Jersey, USA) was used at the concentration 0.1 lg/mL for ELISA experiments and was covalently linked to magnetic beads coupled with sheep anti-mouse IgG (see below).
For immunofluorescence experiments, PE-labelled mouse anti-CD152 mAb (IgG, produced in Syrian hamster, BioLegend, San Diego, CA), PE-labelled mouse anti-CD28 (IgG, produced in Armenian hamster, BioLegend, San Diego, CA) and PE-labelled mouse anti-CD25 (IgG1, produced in rat, EuroBioScience, Germany) were used at the concentration of 1 lg/mL. Furthermore, FITC-labelled rat anti-mouse CD4 (IgG2b, EuroBioScience, Germany) was used for cell sorting techniques at the concentration of 1 lg/mL. Finally, rat anti-mouse IL2 (IgG2a, k, BioLegend, San Diego, CA) and rat anti-mouse IL10 (IgG1, k, BioLegend, San Diego, CA) were used at the concentration of 0.1 lg/mL for ELISA experiments. . After removing the supernatants, the reaction was stopped by resuspending the beads in 1 mL of 50 mmol/L Tris, pH 7.5 and incubating for 15 minutes with rotational mixing. The cross-linked Dynabeads were washed 3 times with 1 mL PBS, resuspended in 1 mL mouse serum (1:1 v/v in PBS) and incubated with rotational mixing for 2 hour at 4°C. After washing twice with 1 mL PBS, elution was performed using 2 mol/L NaCl, with rotational mixing for 20 minutes at 25°C. The recovered (1 mL) sMHCII protein was dialysed against PBS and concentrated using centrifuge filters (cut off 10,000 Da; centricon 10; Amicon Inc., Beverly, MA).
| Purification of sMHCII proteins

| SDS-PAGE gel
Purified (as described in the previous paragraph) sMHCII protein (20 lL) was loaded onto a 12% SDS-polyacrylamide gel and run in an electrophoresis apparatus (GibcoBRL). Proteins were visualized by silver stain. 25 
| ELISA techniques
Indirect ELISA was performed to verify sMHCII molecule purification, detect IL2 and IL10 cytokines in cell culture supernatants and examine the presence of anti-dsDNA autoantibodies in culture supernatants and serum. Briefly, samples were diluted in 0.05Μ NaHCO 3 , 0.05M Na 2 CO 3 in H 2 Odist (pH = 9.6; coating buffer) coated in 96-well flat bottom plates (Sarstedt), incubated overnight at 4°C and washed 3 times in 5% Tween-20. The remaining proteinfree sites in the plate were blocked by 200 lL/well of 2% PBS-BSA (Albumin Fraction V, Applichem, SaxonyAnhalt, Germany) solution upon incubation for 2 hour at room temperature. After washing 3 times, 100 lL of test antibodies diluted in 0.1% PBS-BSA was added and incubated for 2 hour at room temperature. Extensive washing of the plate was followed by addition of 100 lL of goat anti-mouse IgG coupled to horseradish peroxidise and incubation for 1 hour at room temperature, in dark. Finally, the reaction was developed by adding 100 lL/well of tetramethylbenzidine-H 2 O 2 (TMB Substrate Set, TMB Substrate A and B, BioLegend, San Diego, CA) for 5 minutes. The enzymatic reaction was stopped with 50 mL H 2 SO 4 (1 mol/L). Optical density (OD) was measured at 450 nm using a Titertec ELISA photometer (Digiscan, ASYSHitech, GmbH; Engendorf, Austria).
| In vivo inducible SLE development protocol
BALB/c mice received an intraperitoneal injection of 0,5 mL pristane (2,6,10,14 tetramethylpentadecane), an isoprenoid alkane found at high concentration in mineral oil.
Mice were submitted to tail bleeding every 15 days after the first 4 weeks and every 3 weeks thereafter. The production of specific anti-dsDNA antibody in the serum was examined to evaluate disease development. Serum was used at the dilution of 1/1000 in ELISA experiments.
| Genomic DNA isolation from mouse tissues
Mouse DNA was isolated from various tissue samples following the protocol described by Wu Qi et al (1995). 26 
| Cell proliferation assays
Spleen cells were cultured in 96-well V-bottomed plates (Sarstedt, Numbrecht, Germany) at the concentration of 1 9 10 6 cells/well in DMEM culture medium (Biosera, Kansas City, USA) supplemented with 10% foetal bovine serum (FBS, Gibco) at a final volume of 200 lL with or without DNA (in various concentrations) and with or without sMHCII (30 ng/mL, 7, 20 ) and processed for 3 HTdR incorporation assays after 4 days of culture. The cultures were pulsed with 1 lCi of 3 HTdR (ICN, Costa Mesa, CA)
18 hour prior to harvest. After transferring the cells on to cellulose filters, these were put in scintillation fluid (toluene-omnifluor; 1.38 g/L, NEN) and counted using a LKB beta-counter (Finland).
| Cell cultures
Spleen cells were cultured in 24-well plates (Sarstedt) at the concentration of 1 9 10 6 cells/mL in DMEM culture medium supplemented with 10% foetal bovine serum at a final volume of 1 mL with or without 45 or 90 pg/mL dsDNA and with or without sMHCII (30 ng/mL) for 4 days. Culture supernatants (1:2 dilutions) were examined for the presence or specific anti-dsDNA by ELISA. In another set of experiments, 1 9 10 6 macrophages isolated following overnight adherence of spleen cells were pulsed with 90 pg/mL dsDNA for 24 hour, to allow antigen presentation. After eliminating free antigen, 10 6 purified CD4 + T cells were added to the cultures in the presence or not of sMHCII d or sMHCII k (30 ng/mL) and incubated for 24 hour. Upon culture termination, cells were processed to immunofluorescence and culture supernatants to ELISA for the determination of IL-2 or IL-10 levels.
2.10 | CD4-positive cell purification and immunofluorescence Spleen cells were cultured for 24 hour in 10 mm petri dishes at the concentration of 1 9 10 6 cells/mL. Upon elimination of adherent cells, the remaining cells were washed twice in PBS (1 mL) and incubated with PBS-BSA 2% buffer for blocking the remaining protein-free sites at room temperature for 30 minutes. After extensive washing with PBS, the cells were incubated with FITC-or PE-conjugated antibodies. After washing, the cells were diluted in the appropriate volume of PBS and processed to FACS cell sorter isolation or flow cytometry analysis ( Figure S1 ). In the case of cell sorting, the cells were set in culture for further experimentation.
| Statistical analysis
Data were analysed with two-tailed paired (in vitro experiments) or unpaired (in vivo experiments) Student's t test. P-values <.05 were considered significant (*), values <.01 were considered very significant (**), and values <.001 and <.0001 were considered highly significant (*** and ****). Statistics were performed using GRAPHPAD Prism 6.01 (GRAPHPAD Software, La Jolla, CA).
| RESULTS
In an effort to alleviate SLE symptoms using sMHCII molecules, an in vitro as well as in vivo murine experimental SLE models were designed.
| Development of an in vitro SLE experimental model
Various mechanisms towards clonal deletion and/or development of suppressor mechanisms account for the maintenance of tolerance to self antigens. Among the parameters that account for tolerance development is the concentration of an antigen. Low or high doses of an antigen result in low-zone or high-zone tolerance achievement, respectively. Concentrating on the antigenic stimulus of dsDNA in the development of SLE, it was initially attempted to break tolerance vis-a-vis dsDNA in vitro.
To this extend, na€ ıve spleen cells from BALB/c mice were incubated with various amounts of dsDNA ranging from 23 ng/mL to 5.5 pg/mL and examined as to their proliferative activity using 3 HTdR uptake techniques (Figure 1A) . Following the results of these experiments, the concentrations of 45 and 90 pg/mL dsDNA, which showed a 50% and 60% increase of proliferation as compared to control cells respectively, were considered to be able to break tolerance and were therefore assessed as to their ability to mount an anti-dsDNA response. Thus, na€ ıve spleen cells were incubated with 45 or 90 pg/mL dsDNA for 4 days, and culture supernatants were thereafter assayed for the presence of anti-dsDNA IgG ( Figure 1B) . The results showed a statistically significant 81.6% increase (P < .0001) of anti-dsDNA as compared to controls with the use of 90 but not 45 pg/mL dsDNA.
Considering that the concentration of 90 pg/mL dsDNA was breaking DNA tolerance, it was then attempted to reverse the phenomenon using syngeneic or allogeneic sMHCII antigens. To this extend, sMHCII d or sMHCII k proteins were purified from the serum of healthy BALB/c or CBA/J mice, respectively, using magnetic bead protein isolation protocols. As previously described, 7 single-band proteins could be detected in silver-stained SDS-page gel electrophoresis experiments at a molecular weight of 60 kD for both haplotypes tested ( Figure S1A ). The isolated proteins were concentrated, dialysed against PBS and tested for their specificity by ELISA ( Figure S1B ). Protein concentration was evaluated using the Lοwry protein determination assay. These preparations were used thereafter for all experiments. Thus, na€ ıve spleen cells were incubated with 90 pg/mL dsDNA, and 1 day after culture initiation, sMHCII d or sMHCII k proteins were added at a concentration of 30 pg/ mL. Upon culture termination (day 4), the cells were tested for their proliferative ability ( Figure 1C) , while culture supernatants were tested for the presence of anti-dsDNA F I G U R E 1 Breaking tolerance to dsDNA in vitro. Spleen cells from BALB/c mice were incubated with 23 ng/mL to 5.5 pg/mL dsDNA and examined as to their proliferative activity using , and culture supernatants were examined for the presence of specific anti-dsDNA antibody after 4 days of culture by ELISA. The results represent the mean of 3 experiments and are expressed as pg/mL AE SEM. **P < .005, ***P < .001, ****P < .0001 IgG ( Figure 1D ). The presence of sMHCII d significantly decreased by 28% 3 HTdR uptake (P = .0017) as compared to dsDNA-treated controls ( Figure 1C ). In those experiments, sMHCII k could not decrease in a statistically significant manner proliferation of dsDNA-treated spleen cells, possibly due to an allogeneic effect (see discussion). However, both sMHCII d and sMHCII k proteins could significantly reduce specific anti-dsDNA IgG production by 39 (P = .0006) and 38% (P = .0025) as compared to dsDNAtreated controls, respectively. To evaluate the suppressive effect of sMHCII d and sMHCII k proteins, T cell marker analysis was performed using flow cytometry analysis. In such experiments, na€ ıve spleen macrophages were pulsed with dsDNA for 24 hour and upon antigen removal, na€ ıve, cell sorter-purified CD4 + cells ( Figure S2A ) were added to the cultures in the presence or not of sMHCII d and sMHCII k proteins.
Forty-eight hours later, non-adherent cells were immunostained with anti-CD28, -CTLA-4 or -CD25 monoclonal antibodies, and the percentage of CD4 + CD28 + , CD4 + CTLA-4 + and CD4 + CD25 + cells was evaluated by flow cytometry analysis ( Figure 2 , Figure S2B ). The addition of sMHCII d and sMHCII k to the cultures significantly decreased CD4 + CD28 + cells by 47.5 (P = .0062) and 27.2% (P = .0409) as compared to dsDNA-treated controls, respectively, while increasing CD4 + CTLA-4 + by 122 (P = .0032) and 139% (P = .0106), respectively (Figure 2A, B) . However, the treatment did not show any significant changes in the percentage of CD4 + CD25 + cells (data not shown). When culture supernatants from these experiments were tested for their content in IL-2 and IL-10 cytokines, a significant decrease by 14 (P = .0304) and 35% (P < .0001) of IL-2 and a significant increase by 30 (P = .0202) and 64% (P < .0001) of IL-10 were observed upon addition of sMHCII d and sMHCII k to the dsDNA-treated cultures, respectively ( Figure 2C, D) . Thus, the results indicated that tolerance to dsDNA could be broken in vitro, as manifested by increased proliferation and specific anti-dsDNA antibody production, while sMHCII d and sMHCII k proteins could rescue this phenotype by increasing the numbers of suppressive CD4 + CTLA-4 + cell populations, inducing IL-10, decreasing the numbers of CD4 + CD28 + cells and reducing the levels of IL-2. Therefore, it was then inquired whether similar effects could be observed in vivo.
| Development of an in vivo SLE experimental model
The experimental SLE model implicated in the present study consisted of pristane administration to BALB/c The results represent the mean of 3 experiments and are expressed as pg/mL AE SD. *P < .01, **P < .005, ***P < .001, ****P < .0001 mice. 21 Following such treatment, SLE establishment is a relatively slow procedure, manifesting the first symptoms 2 months after injection. Upon definition of a scoring rate depending on the phenotypical appearance of pristane-treated animals (Table 1) , a quantification of the symptoms was performed ( Figure 3A ). Eight months after treatment initiation, the animals were showing severe SLE symptoms characterized by reduced activity, no response to auditory stimuli, severe rash and obesity ( Figure 3A) . Kinetic experiments could detect significant increase by 244% (P = .0004) of anti-dsDNA IgG in the serum 2 months after treatment initiation, as compared to untreated controls. The levels of anti-dsDNA IgG declined to 8 ng/mL 3 months after treatment initiation and stabilized at 6 ng/ mL thereafter, which, however, were still showing a statistically significant increase (P = .0032) as compared to untreated controls ( Figure 3B ).
To evaluate whether sMHCII proteins could alleviate SLE symptoms, 0.3 lg/gr of body weight was injected to pristane-treated mice, 1 month after symptom manifestation. The levels of anti-dsDNA in the serum were examined 1, 3 or 7 days after sMHCII d erythematosus (SLE) model. BALB/c mice were injected with 0.5 mL pristane and examined thereafter for SLE symptom development (A). Symptom scoring was based on phenotypes described in supplement Table 1 and evaluated activity, response to stimulus, skin rash/coat and obesity with scores ranging from 0-3. The percentage of SLE symptom magnitude represents the addition of individual scores in each evaluated parameter vis-a-vis the maximal score of each parameter. Symptoms of 11 animals were evaluated through time (AESD). Detection of specific anti-dsDNA antibody in the serum of animals treated with pristane (B). The presence of specific antidsDNA IgG antibody in the serum was detected by ELISA. The results represent the mean of 10 animals tested and are expressed as ng/mL AE SD. *P < .01, **P < .005, ***P < .001, ****P < .0001 injections of sMHCII d or sMHCII k proteins (data not shown). Importantly, the phenotypic symptoms of sMHCIItreated mice were similar to the symptoms at the time of treatment initiation, without worsening, at least during the time period of experimentation ( Figure 4B ). Examining the effect of sMHCII administration on the CD4 + T cell populations in vivo, pristane-treated animals were sacrificed 7 days after sMHCII administration and spleen cells were processed to immunostaining, followed by flow cytometry analysis ( Figure 5) . Indeed, the results showed that the pristane treatment significantly decreased by 37% (P = .0013) the levels of CD4 + CTLA-4 + in the spleen as compared to untreated animals, while the administration of sMHCII d or sMHCII k proteins increased by 29 (P = .0051) and 36% (P = .0216) the levels of CD4 + CTLA-4 + as compared to the pristane-treated animals ( Figure 5A ). In addition, the levels of CD4 + CD25 + cells increased by 21 (P = .0166) and 13% (P = .0057) as compared to the pristane-treated animals ( Figure 5B ). The levels of CD4 + CD28 + cells did not show any statistically significant variations with or without the various treatments ( Figure 5C ).
cells. Taking advantage of the acquired knowledge on sMHCII antigens, which have been attributed an important role in maintaining tolerance to self or tolerogenic antigens, the present study attempted to alleviate SLE symptoms using syngeneic or allogeneic sMHCII proteins. Both in vitro and in vivo developed experimental models converged towards the beneficial effect of sMHCII, which could significantly decrease specific anti-dsDNA antibody production and induce suppressive markers to the host. The in vitro experimental model developed in this study consisted of breaking tolerance to DNA. Using cell proliferation assays, in a wide spectrum of DNA concentrations, the high-and low-zone tolerance as well as the concentrations breaking tolerance could be defined. Thus, doses up to 22 pg/mL were included in the low-dose tolerance, and doses from 360 to 1400 pg/mL were included in the high-zone tolerance, whereas doses from 45-180 pg/mL and 3 to 23 ng/mL were shown to break tolerance. Selecting the doses of 45 and 90 pg/mL dsDNA, it was shown that only the dose of 90 pg/mL could increase in a statistically significant manner-specific antidsDNA IgG production, which was used as an indicative DNA tolerance-breaking marker throughout experimentations in the present study.
Soluble MHCII was purified from normal syngeneic or allogeneic mouse serum and applied to the described experimental models. According to recent observations, sMHCII proteins are loaded with self/tolerogenic molecules and play an important role in tolerance maintenance by competing with membrane MHCII molecules, inducing suppressive markers and cytokines, blocking T cell activation, pushing thus the immune system towards suppression. 7, 8, 20 If tolerance to self is to be maintained by sMHCII molecules, it implicates that sMHCII in the serum is loaded with all possible self-antigenic epitopes, blocking thus antigen-specific T cells. In accordance with this hypothesis, some sMHCII molecules in healthy/normal mice should be loaded with DNA-specific antigenic epitopes, which could compete with immunogenic processes for anti-DNA response development. Indeed, mass spectroscopy analysis has revealed SLE-related antigenic epitopes loaded onto serum sMHCII molecules. 7 Another important issue that needs to be considered is the possibility to use allogeneic sMHCII proteins. Application of these molecules to humans would be of minimal interest, if only HLA-matched donors could be used for the isolation of sMHCII molecules. Using allogeneic sMHCII proteins, one would have to face the allogeneic reaction, but at the same time, one would expect to be able to block antigen-specific autoreactive T cells. Looking closely into the MHC/TCR interactions, three types of interactions do occur: (1) MHC-antigen, (2) MHC-TCR and (3) TCR-antigen. In case of allogeneic organisms, although host TCR would interact with lower affinity with specific donor sMHCII antigen loads, the development of allo-MHC-TCR interactions could provide an overall effect in favour of the host vis-a-vis suppression of a specific immune response.
The results presented in this report are in favour of such hypothesis. Although only syngeneic sMHCII could significantly reduce the DNA-induced proliferation of spleen cells, both syngeneic and allogeneic sMHCII reduced in a statistically significant manner-specific anti-dsDNA antibody production. The inability of allogeneic sMHCII to reduce the DNA-induced cell proliferation could be of an indirect effect, summing up the suppression towards antigen-specific T cells and the stimulation towards allogeneic T cells. In all other cases tested, the addition of both types of sMHCII to the DNA-stimulated cell system reduced the percentage of CD4 + CD28 + cells and IL-2 production (which account for immunostimulation), while increasing the percentage of CD4 + CTLA-4 + cells and IL-10 production (which account for immune suppression).
To test the above hypothesis in vivo, the experimental model of pristane-induced SLE in BALB/c mice was applied. 21 Disease development was a slow procedure, characterized by specific phenotypic symptoms including changes in activity, response to stimulus, skin rash, coat appearance and obesity. Scoring the severity of these symptoms, pristane-treated BALB/c mice started showing quantitative SLE symptoms 2 months after treatment initiation and worsened as time was going by. The first signs of disease development were accompanied with the highest levels of anti-dsDNA antibodies in the serum, which although declined by the forth month, they were maintained at significantly higher levels as compared to healthy untreated animals. Administration of syngeneic or allogeneic sMHCII proteins significantly decreased the levels of anti-dsDNA antibodies in the serum when tested 1, 3 or 7 days after administration. Monthly injections of sMHCII proteins could maintain animals at reasonably good phenotypic appearance, significantly better than animals that did not receive the treatments. The reduction of anti-dsDNA antibody levels in the serum and the phenotypic good appearance of sMHCII-treated mine was accompanied by statistically significant increase of the CD4 + CTLA-4 + and CD4 + CD25 + cell populations in the spleen, indicating that the sMHCII treatment was responsible for the development of suppressive mechanisms.
In conclusion, the presented results point to a hopeful direction, where sMHCII molecules could be protective to SLE and alleviate symptom severity. Further studies defining doses and timing of administration could provide better results and definite treatment of the disease. Extrapolation of the herein tested hypothesis to other autoimmune diseases could make sMHCII proteins the choice treatment for many other pathologic conditions. Due to MHC polymorphism, the efforts to universally define self-antigenic epitopes, responsible for the development of autoimmunities, have been unsuccessful and therefore re-enforcement of an organism to tolerance induction is considered fruitless. To this extend, sMHCII proteins could provide a solution to autoimmunities. The in-depth study of sMHCII biochemistry and construction of personalized antigenspecific loaded proteins is within the goals of future research. However, until having the necessary technological facilities for the construction of such products, serum sMHCII isolates from healthy individuals could provide a universal alternative treatment not only for SLE, but other autoimmunities as well.
